The potential and the pitfalls of β-adrenoceptor agonists for the management of skeletal muscle wasting

Pharmacology and Therapeutics

Volumn 120, Issue 3, 2008, Pages 219-232

  Ryall, James G ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

AKAP; Atrophy; Beta adrenoceptor; Heart; Hypertrophy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CIMATEROL; CLENBUTEROL; FENOTEROL; FORMOTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENERGIC SYSTEM; BODY TEMPERATURE; BURN; CACHEXIA; CHILL; CHRONIC KIDNEY FAILURE; DENERVATION; DRUG MECHANISM; EPISTAXIS; FEVER; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; METABOLIC DISORDER; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE FUNCTION; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SEPSIS; SIDE EFFECT; SWEATING; TREMOR; URTICARIA;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; MUSCLE PROTEINS; MUSCLE WEAKNESS; MUSCULAR ATROPHY; MUSCULAR DISORDERS, ATROPHIC; SIGNAL TRANSDUCTION;

EID: 56049103744     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.06.003     Document Type: Review

References (196)

1. Abramson M.J., Walters J., and Walters E.H. Adverse effects of beta-agonists: are they clinically relevant?. Am J Respir Med 2 (2003) 287-297
2. 2-adrenergic agonist clenbuterol on the growth of fast- and slow-twitch skeletal muscle of the dystrophic (C57BL6J dy2J/dy2J) mouse. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 111 (1995) 397-403
3. Ahmet I., Krawczyk M., Heller P., Moon C., Lakatta E.G., and Talan M.I. Beneficial effects of chronic pharmacological manipulation of β-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110 (2004) 1083-1090
4. 1 AR blocker in dilated cardiomyopathy post-myocardial infarction. J Pharmacol Exp Ther 325 (2008) 491-499
5. 2-adrenergic receptors (β2AR) enhances therapeutic effectiveness of β1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10 (2005) 289-296
6. 2 adrenergic agonist. Br J Pharmacol 147 (2006) 412-421
7. Anamourlis C., Badenhorst D., Gibbs M., Correia R., Veliotes D., Osadchii O., et al. Phosphodiesterase inhibition promotes the transition from compensated hypertrophy to cardiac dilatation in rats. Pflugers Arch 451 (2006) 526-533
8. 2-adrenoceptor agonist bronchodilator. Life Sci 52 (1993) 2145-2160
9. Argilés J.M., López-Soriano F.J., and Busquets S. Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol 40 (2008) 1674-1678
10. Attaix D., Ventadour S., Codran A., Bechet D., Taillandier D., and Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 41 (2005) 173-186
11. Au D.H., Lemaitre R.N., Curtis J.R., Smith N.L., and Psaty B.M. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Resp Crit Care Med 161 (2000) 827-830
12. 2-adrenoceptor agonist prodrug BRL-47672 impairs rat skeletal muscle function by inducing a comprehensive shift to a faster muscle phenotype. J Pharmacol Exp Ther 319 (2006) 439-446
13. Baldi A., Bontempo V., Cheli F., Corino C., and Polidori F. Hormonal and metabolic responses to the stress of transport and slaughterhouse procedures in clenbuterol-fed pigs. J Vet Med 41 (1994) 189-196
14. Baldwin K.M., Ernst S.B., Mullin W.J., Schrader L.F., and Herrick R.E. Exercise capacity and cardiac function of rats with drug-induced cardiac enlargement. J Appl Physiol 52 (1982) 591-595
15. Bar A., and Pette D. Three fast myosin heavy chains in adult rat skeletal muscle. FEBS Lett 235 (1988) 153-155
16. Bauman A.L., Michel J.J., Henson E., Dodge-Kafka K.L., and Kapiloff M.S. The mAKAP signalosome and cardiac myocyte hypertrophy. IUBMB Life 59 (2007) 163-169
17. 2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. Am J Physiol Endocrinol Metab 292 (2007) E702-E708
18. 2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol 96 (2004) 1385-1392
19. Beitzel F., Sillence M.N., and Lynch G.S. β-Adrenoceptor signaling in regenerating skeletal muscle after β-agonist administration. Am J Physiol Endocrinol Metab 293 (2007) E932-E940
20. Benedict N., Seybert A., and Mathier M.A. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 29 (2007) 2134-2153
21. Benjamin I.J., Jalil J.E., Tan L.B., Cho K., Weber K.T., and Clark W.A. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65 (1989) 657-670
22. Benson D.W., Foley-Nelson T., Chance W.T., Zhang F.S., James J.H., and Fischer J.E. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 50 (1991) 1-5
23. Berchtold M.W., Brinkmeier H., and Muntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 80 (2000) 1215-1265
24. Berdeaux R., Goebel N., Banaszynski L., Takemori H., Wandless T., Shelton G.D., et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 13 (2007) 597-603
25. Bers D.M. Cardiac excitation-contraction coupling. Nature 415 (2002) 198-205
26. Beznak M. Hemodynamics during the acute phase of myocardial damage caused by isoproterenol. Can J Biochem Physiol 40 (1962) 25-30
27. Bloom T.J. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can J Physiol Pharmacol 80 (2002) 1132-1135
28. 2+-activation properties of single fibers in soleus muscles from SHR and WKY rats. Am J Physiol 276 (1999) C628-C637
29. Breuillé D., Farge M.C., Rosé F., Arnal M., Attaix D., and Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol 265 (1993) E660-E666
30. Bricout V.A., Serrurier B.D., and Bigard A.X. Clenbuterol treatment affects myosin heavy chain isoforms and MyoD content similarly in intact and regenerated soleus muscles. Acta Physiol Scand 180 (2004) 271-280
31. Buckingham M., Bajard L., Chang T., Daubas P., Hadchouel J., Meilhac S., et al. The formation of skeletal muscle: from somite to limb. J Anat 202 (2003) 59-68
32. Burgess C.D., Beasley R., Crane J., and Pearce N. Adverse effects of beta2-agonists. In: Pauwels R., and O'Byrne P.M. (Eds). β2-Agonists in Asthma Treatment (1997), Marcel Dekker, New York 257-282
33. Burnett A.L. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J Androl 29 (2008) 3-14
34. Busquets S., Figueras M.T., Fuster G., Almendro V., Moore-Carrasco R., Ametller E., et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 64 (2004) 6725-6731
35. 2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 115 (1997) 113-118
36. Carter W.J., Dang A.Q., Faas F.H., and Lynch M.E. Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metabolism 40 (1991) 855-860
37. Casali L., Pinchi G., and Puxeddu E. Doping and respiratory system. Monaldi Arch Chest Dis 67 (2007) 53-62
38. Charge S.B., and Rudnicki M.A. Cellular and molecular regulation of muscle regeneration. Physiol Rev 84 (2004) 209-238
39. 2-adrenoceptor activation. Am J Physiol 263 (1992) E50-E56
40. Clarke B.A., Drujan D., Willis M.S., Murphy L.O., Corpina R.A., Burova E., et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 6 (2007) 376-385
41. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100 (1999) 2210-2212
42. 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 95 (1995) 2367-2372
43. 2+-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 37 (2005) 2134-2146
44. Daaka Y., Luttrell L.M., Ahn S., Della Rocca G.J., Ferguson S.S., Caron M.G., et al. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273 (1998) 685-688
45. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 390 (1997) 88-91
46. Deligiannis A., Björnstad H., Carre F., Heidbüchel H., Kouidi E., Panhuyzen-Goedkoop N.M., et al., ESC Study Group of Sports Cardiology. ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil 13 (2006) 687-694
47. De Mars G., Windelinckx A., Beunen G., Delecluse C., Lefevre J., and Thomis M.A. Polymorphisms in the CNTF and CNTF receptor genes are associated with muscle strength in men and women. J Appl Physiol 102 (2007) 1824-1831
48. 2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Cir Res 102 (2008) 1389-1397
49. DeWire S.M., Ahn S., Lefkowitz R.J., and Shenoy S.K. β-arrestins and cell signaling. Annu Rev Physiol 69 (2007) 483-510
50. Dodd S.L., Powers S.K., Vrabas I.S., Criswell D., Stetson S., and Hussain R. Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Med Sci Sports Exerc 28 (1996) 669-676
51. Duncan N.D., Williams D.A., and Lynch G.S. Deleterious effects of clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci 98 (2000) 339-347
52. Dupont-Versteegden E.E. Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice. J Appl Physiol 80 (1996) 734-741
53. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 96 (1999) 7059-7064
54. 2-adrenergic receptors in mouse liver alters the expression of gluconeogenic and glycolytic enzymes. Am J Physiol Endocrinol Metab 288 (2005) E715-E722
55. Farges M.C., Balcerzak D., Fisher B.D., Attaix D., Bechet D., Ferrara M., et al. Increased muscle proteolysis after local trauma mainly reflects macrophage-associated lysosomal proteolysis. Am J Physiol Endocrinol Metab 282 (2002) E326-E335
56. Feldman D.S., Elton T.S., Sun B., Martin M.M., and Ziolo M.T. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med 5 (2008) 208-218
57. Fielitz J., Kim M.S., Shelton J.M., Latif S., Spencer J.A., Glass D.J., et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 117 (2007) 2486-2495
58. Fioretti P., Brower R.W., Meester G.T., and Serruys P.W. Interaction of left ventricular relaxation and filling during early diastole in human subjects. Am J Cardiol 46 (1980) 197-203
59. Fisher A.A., Davis M.W., and McGill D.A. Acute myocardial infarction associated with albuterol. Ann Pharmacother 38 (2004) 2045-2049
60. Fleury C., Neverova M., Collins S., Raimbault S., Champigny O., Levi-Meyrueis C., et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 15 (1997) 269-272
61. Florini J.R., Ewton D.Z., and Coolican S.A. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 17 (1996) 481-517
62. 2-adrenoceptors. Proc Natl Acad Sci U S A 100 (2003) 14475-14480
63. Forsberg N.E., Ilian M.A., Ali-Bar A., Cheeke P.R., and Wehr N.B. Effects of cimaterol on rabbit growth and myofibrillar protein degradation and on calcium-dependent proteinase and calpastatin activities in skeletal muscle. J Anim Sci 67 (1989) 3313-3321
64. Fowler E.G., Graves M.C., Wetzel G.T., and Spencer M.J. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology 62 (2004) 1006-1008
65. Frost R.A., and Lang C.H. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 103 (2007) 378-387
66. Geiger P.C., Cody M.J., Macken R.L., Bayrd M.E., Fang Y.H., and Sieck G.C. Mechanisms underlying increased force generation by rat diaphragm muscle fibers during development. J Appl Physiol 90 (2001) 380-388
67. Glass D.J. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5 (2003) 87-90
68. Goldstein D.R., Dobbs T., Krull B., and Plumb V.J. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 91 (1998) 780-784
69. Gosmanov A.R., Wong J.A., and Thomason D.B. Duality of G protein-coupled mechanisms for β-adrenergic activation of NKCC activity in skeletal muscle. Am J Physiol Cell Physiol 283 (2002) C1025-C1032
70. Gregorevic P., Ryall J.G., Plant D.R., Sillence M.N., and Lynch G.S. Chronic β-agonist administration affects cardiac function of adult but not old rats, independent of β-adrenoceptor density. Am J Physiol Heart Circ Physiol 289 (2005) H344-H349
71. Grifone R., Laclef C., Spitz F., Lopez S., Demignon J., Guidotti J.E., et al. Six1 and Eya1 expression can reprogram adult muscle from the slow-twitch phenotype into the fast-twitch phenotype. Mol Cell Biol 24 (2004) 6253-6267
72. Guldner N.W., Klapproth P., Grossherr M., Stephan M., Rumpel E., Noel R., et al. Clenbuterol-supported dynamic training of skeletal muscle ventricles against systemic load: a key for powerful circulatory assist?. Circulation 101 (2000) 2213-2219
73. Gurevich E.V., and Gurevich V.V. Arrestins: ubiquitous regulators of cellular signaling pathways. Genome Biol 7 (2006) 236
74. Gutmann E., and Hanzliková V. Motor unit in old age. Nature 209 (1966) 921-922
75. Hanai J., Cao P., Tanksale P., Imamura S., Koshimizu E., Zhao J., et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 117 (2007) 3940-3951
76. Handschin C., Chin S., Li P., Liu F., Maratos-Flier E., Lebrasseur N.K., et al. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1a muscle-specific knock-out animals. J Biol Chem 282 (2007) 30014-30021
77. Harcourt L.J., Schertzer J.D., Ryall J.G., and Lynch G.S. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscul Disord 17 (2007) 47-55
78. 2+-ATPase function in cardiac and slow-twitch skeletal muscle sarcoplasmic reticulum. Mol Cell Biochem 142 (1995) 131-138
79. 2 agonist) treatment on muscle growth and calpain proteinase (EC 3.4.22.17) and calpastatin activities in lambs. Br J Nutr 60 (1988) 645-652
80. Hinkle R.T., Dolan E., Cody D.B., Bauer M.B., and Isfort R.J. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle Nerve 32 (2005) 775-781
81. 2-adrenergic receptor. Muscle Nerve 25 (2002) 729-734
82. Hoffman R.J., Hoffman R.S., Freyberg C.L., Poppenga R.H., and Nelson L.S. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. J Toxicol Clin Toxicol 39 (2001) 339-344
83. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem Soc Trans 31 (2003) 1120-1124
84. Houmard J.A., Weidner M.L., Gavigan K.E., Tyndall G.L., Hickey M.S., and Alshami A. Fiber type and citrate synthase activity in the human gastrocnemius and vastus lateralis with aging. J Appl Physiol 85 (1998) 1337-1341
85. Hudlická O., and Price S. Effects of torbafylline, pentoxifylline and buflomedil on vascularisation and fibre type of rat skeletal muscles subjected to limited blood supply. Br J Pharmacol 99 (1990) 786-790
86. Jeppsson A.B., Waldeck B., and Widmark E. Further studies on the cardiomegaly induced by β-adrenoceptor agonists. Acta Pharm Toxicol (Copenh) 58 (1986) 121-125
87. Jin J., Li X., Gygi S.P., and Harper J.W. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 447 (2007) 1135-1138
88. 2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation. Int J Obes (Lond) 31 (2007) 813-819
89. 3-adrenoceptor-deficient brown adipocytes. Am J Physiol Endocrinol Metab 283 (2002) E146-153
90. Kamalakkannan G., Petrilli C.M., George I., LaManca J., McLaughlin B.T., Shane E., et al. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transplant 27 (2008) 457-461
91. Kass D.A., Champion H.C., and Beavo J.A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101 (2007) 1084-1095
92. Kendall M.J., and Haffner C.A. The acute unwanted effects of (2 receptor agonist therapy. In: Beasley R., and Pearce N.E. (Eds). The Role of Beta Receptor Agonist Therapy in Asthma Mortality (1993), CRC Press, Boca Raton, Florida 163-199
93. Kentish J.C., McCloskey D.T., Layland J., Palmer S., Leiden J.M., Martin A.F., et al. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res 88 (2001) 1059-1065
94. Kierzkowska B., Stańczyk J., and Kasprzak J.D. Myocardial infarction in a 17-year-old body builder using clenbuterol. Circ J 69 (2005) 1144-1146
95. 2-Adrenergic and several other G protein-coupled receptors in human atrial membranes activate both Gs and Gi. Circ Res 87 (2000) 705-709
96. 2+/PKC, and PI3K/Akt signaling pathways in mouse embryonic stem cells. J Cell Biochem 104 (2008) 1407-1420
97. Kim M.S., Fielitz J., McAnally J., Shelton J.M., Lemon D.D., McKinsey T.A., et al. Protein kinase D1 stimulates MEF2 activity in skeletal muscle and enhances muscle performance. Mol Cell Biol 28 (2008) 3600-3609
98. 2-adrenoceptors in rat skeletal muscles. Biochem Pharmacol 42 (1991) 1783-1789
99. 2-agonists have an ergogenic potential in non-asthmatic competitive athletes?. Sports Med 37 (2007) 95-102
100. Kissel J.T., McDermott M.P., Mendell J.R., King W.M., Pandya S., Griggs R.C., et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57 (2001) 1434-1440
101. Kline W.O., Panaro F.J., Yang H., and Bodine S.C. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol 102 (2007) 740-747
102. Lagirand-Cantaloube J., Offner N., Csibi A., Leibovitch M.P., Batonnet-Pichon S., Tintignac L.A., et al. The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 27 (2008) 1266-1276
103. Lang C.H., Huber D., and Frost R.A. Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol 292 (2007) R328-R336
104. Lesourd B., and Mazari L. Nutrition and immunity in the elderly. Proc Nutr Soc 58 (1999) 685-695
105. Libretto S.E. A review of the toxicology of salbutamol (albuterol). Arch Toxicol 68 (1994) 213-216
106. Liggett S.B., Cresci S., Kelly R.J., Syed F.M., Matkovich S.J., Hahn H.S., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14 (2008) 510-517
107. Lohse M.J., Engelhardt S., and Eschenhagen T. What is the role of β-adrenergic signaling in heart failure?. Circ Res 93 (2003) 896-906
108. Luttrell L.M., and Lefkowitz R.J. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115 (2002) 455-465
109. Lynch G.S. Beta-agonists. In: Bahrke M., and Yesalis C. (Eds). Performance-enhancing substances in sport and exercise (2002), Human Kinetics, Champaign, Illinois 47-64
110. Lynch G.S., Hinkle R.T., and Faulkner J.A. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment. Exp Physiol 85 (2000) 295-299
111. Lynch G.S., and Ryall J.G. Role of β-adrenoceptor signaling in skeletal muscle - implications for muscle wasting and disease. Physiol Rev 88 (2008) 729-767
112. Lynch G.S., Schertzer J.D., and Ryall J.G. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 113 (2007) 461-487
113. Lynch G.S., Schertzer J.D., and Ryall J.G. Anabolic agents for improving muscle regeneration and function after injury. Clin Exp Pharm Physiol 35 (2008) 852-858
114. Maltin C.A., Delday M.I., Watson J.S., Heys S.D., Nevison I.M., Ritchie I.K., et al. Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond) 84 (1993) 651-654
115. 2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?. Drugs 67 (2007) 503-515
116. Michel J.J., and Scott J.D. AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 42 (2002) 235-257
117. 2-adrenoceptor agonists for the management of muscle wasting. Br J Pharmacol 147 (2006) 583-586
118. Molenaar P., and Parsonage W.A. Fundamental considerations of β-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 26 (2005) 368-375
119. 2-adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol 375 (2007) 11-28
120. 2-adrenoceptor agonist salmeterol are dependent on route of administration. Am J Physiol 267 (1994) E475-E484
121. Murad N., and Tucci P.J.F. Isoproterenol-induced hypertrophy may result in distinct left ventricular changes. Clin Exp Pharm Physiol 27 (2000) 352-357
122. Murga C., Fukuhara S., and Gutkind J.S. A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. J Biol Chem 275 (2000) 12069-12073
123. Murphy R.M., Goodman C.A., McKenna M.J., Bennie J., Leikis M., and Lamb G.D. Calpain-3 is autolyzed and hence activated in human skeletal muscle 24 h following a single bout of eccentric exercise. J Appl Physiol 103 (2007) 926-931
124. Navegantes L.C., Migliorini R.H., and Kettelhut I.C. Adrenergic control of protein metabolism in skeletal muscle. Curr Opin Clin Nutr Metab Care 5 (2002) 281-286
125. 2-adrenoceptors and cAMP. Am J Physiol Endocrinol Metab 281 (2001) E449-E454
126. Nizet T.A., Broeders M.E., and Folgering H.T. Tremor side effects of salbutamol, quantified by a laser pointer technique. Respir Med 98 (2004) 844-850
127. Oh M., Rybkin I.I., Copeland V., Czubryt M.P., Shelton J.M., van Rooij E., et al. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Mol Cell Biol 25 (2005) 6629-6638
128. 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell 67 (1991) 723-730
129. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ Res 100 (2007) 309-327
130. Pack R.J., Alley M.R., Dallimore J.A., Lapwood K.R., Burgess C., and Crane J. The myocardial effects of fenoterol, isoprenaline and salbutamol in normoxic and hypoxic sheep. Int J Exp Path 75 (1994) 357-362
131. Pan S.J., Hancock J., Ding Z., Fogt D., Lee M., and Ivy J.L. Effects of clenbuterol on insulin resistance in conscious obese Zucker rats. Am J Physiol Endocrinol Metab 280 (2001) E554-561
132. Pare G.C., Bauman A.L., McHenry M., Michel J.J., Dodge-Kafka K.L., and Kapiloff M.S. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J Cell Sci 118 (2005) 5637-5646
133. Parr T., Bardsley R.G., Gilmour R.S., and Buttery P.J. Changes in calpain and calpastatin mRNA induced by β-adrenergic stimulation of bovine skeletal muscle. Eur J Biochem 208 (1992) 333-339
134. Parr M.K., Koehler K., Geyer H., Guddat S., and Schänzer W. Clenbuterol marketed as dietary supplement. Biomed Chromatogr 22 (2008) 298-300
135. Pearen M.A., Myers S.A., Raichur S., Ryall J.G., Lynch G.S., and Muscat G.E. The orphan nuclear receptor, NOR-1, a target of β-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 149 (2008) 2853-2865
136. Pearen M.A., Ryall J.G., Maxwell M.A., Ohkura N., Lynch G.S., and Muscat G.E. The orphan nuclear receptor, NOR-1, is a target of β-adrenergic signaling in skeletal muscle. Endocrinology 147 (2006) 5217-5227
137. Peeters M.A., van Schoor N.M., van Rossum E.F., Visser M., and Lips P. The relationship between cortisol, muscle mass and muscle strength in older persons and the role of genetic variations in the glucocorticoid receptor. Clin Endocrinol 69 (2008) 673-682
138. Pellegrino M.A., D'Antona G., Bortolotto S., Boschi F., Pastoris O., Bottinelli R., et al. Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice. Exp Physiol 89 (2004) 89-100
139. Petrou M., Clarke S., Morrison K., Bowles C., Dunn M., and Yacoub M. Clenbuterol increases stroke power and contractile speed of skeletal muscle for cardiac assist. Circulation 99 (1999) 713-720
140. Pogwizd S.M., Schlotthaurer K., Li L., Weilong Y., and Bers D.M. Arrhythmogenesis and contractile dysfunction in heart failure. Circ Res 88 (2001) 1159-1167
141. 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 592-599
142. Prather I.D., Brown D.E., North P., and Wilson J.R. Clenbuterol: a substitute for anabolic steroids. Med Sci Sports Exer 27 (1995) 1118-1121
143. Pringle T.D., Lonergan S.M., Calkins C.R., Jones S.J., Miller P.S., and Koohmaraie M. Temporal response of rabbits to β-adrenergic agonist feeding: tissue weight, calpains and calpastatin activities, and nucleic acid and protein concentrations. J Anim Sci 72 (1994) 68-74
144. Ramos F., Silveira I., Silva J.M., Barbosa J., Cruz C., Martins J., et al. Proposed guidelines for clenbuterol food poisoning. Am J Med 117 (2004) 362
145. Reiken S., Lacampagne A., Zhou H., Kherani A., Lehnart S.E., Ward C., et al. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol 160 (2003) 919-928
146. Reynolds J.G., McCalmon S.A., Donaghey J.A., and Naya F.J. Deregulated PKA signaling and myospryn expression in muscular dystrophy. J Biol Chem 283 (2008) 8070-8074
147. Reynolds J.G., McCalmon S.A., Tomczyk T., and Naya F.J. Identification and mapping of protein kinase A binding sites in the costameric protein myospryn. Biochim Biophys Acta 1773 (2007) 891-902
148. Röckl K.S., Witczak C.A., and Goodyear L.J. Signaling mechanisms in skeletal muscle: acute responses and chronic adaptations to exercise. IUBMB Life 60 (2008) 145-153
149. Roth S.M., Metter E.J., Lee M.R., Hurley B.F., and Ferrell R.E. C174T polymorphism in the CNTF receptor gene is associated with fat-free mass in men and women. J Appl Physiol 95 (2003) 1425-1430
150. Ruehr M.L., Russell M.A., Ferguson D.G., Bhat M., Ma J., Damron D.S., et al. Targeting of protein kinase A by muscle A kinase-anchoring protein (mAKAP) regulates phosphorylation and function of the skeletal muscle ryanodine receptor. J Biol Chem 278 (2003) 24831-24836
151. 2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol 283 (2002) R1386-R1394
152. 2-Agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 555 (2004) 175-188
153. Ryall J.G., Schertzer J.D., and Lynch G.S. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J Gerontol A Biol Sci Med Sci 62 (2007) 813-823
154. Ryall J.G., Schertzer J.D., Alabakis T.M., Gehrig S.M., Plant D.R., and Lynch G.S. Intramuscular β2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury. J Appl Physiol 105 (2008) 165-172
155. 2+-ATPase protein and activity. J Appl Physiol 294 (2008) H2587-H2595
156. 2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 147 (2006) 587-595
157. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest 125 (2004) 2309-2321
158. Samec S., Seydoux J., and Dulloo A.G. Post-starvation gene expression of skeletal muscle uncoupling protein 2 and uncoupling protein 3 in response to dietary fat levels and fatty acid composition: a link with insulin resistance. Diabetes 48 (1999) 436-441
159. Schechter E., Hoffman R.S., Stajic M., McGee M.P., Cuevas S., and Tarabar A. Pulmonary edema and respiratory failure associated with clenbuterol exposure. Am J Emerg Med 25 (2007) 735.e1-735.e3
160. 2+-ATPase activity in aged rat skeletal muscle. Am J Physiol Endocrinol Metab 288 (2005) E526-E533
161. Schiaffino S., Sandri M., and Murgia M. Activity-dependent signaling pathways controlling muscle diversity and plasticity. Physiology (Bethesda) 22 (2007) 269-278
162. 2-Adrenergic receptors potentiate glucocorticoid receptor transactivation via G protein βγ-subunits and the phosphoinositide 3-kinase pathway. Mol Endocrinol 15 (2001) 553-564
163. 2-Adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf. J Biol Chem 275 (2000) 25342-25350
164. Sellers L.A., Alderton F., Carruthers A.M., Schindler M., and Humphrey P.P. Receptor isoforms mediate opposing proliferative effects through Gβγ-activated p38 or Akt pathways. Mol Cell Biol 20 (2000) 5974-5985
165. Sensky P.L., Jewell K.K., Ryan K.J., Parr T., Bardsley R.G., and Buttery P.J. Effect of anabolic agents on calpastatin promoters in porcine skeletal muscle and their responsiveness to cyclic adenosine monophosphate- and calcium-related stimuli. J Anim Sci 84 (2006) 2973-2982
166. Shappell N.W., Feil V.J., Smith D.J., Larsen G.L., and McFarland D.C. Response of C2C12 mouse and turkey skeletal muscle cells to the β-adrenergic agonist ractopamine. J Anim Sci 78 (2000) 699-708
167. Sillence M.N., and Matthews M.L. Classical and atypical binding sites for β-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes. Br J Pharmacol 111 (1994) 866-872
168. Simonides W.S., and van Hardeveld C. Thyroid hormone as a determinant of metabolic and contractile phenotype of skeletal muscle. Thyroid 18 (2008) 205-216
169. Skura C.L., Fowler E.G., Wetzel G.T., Graves M., and Spencer M.J. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70 (2008) 137-143
170. Sneddon A.A., Delday M.I., Steven J., and Maltin C.A. Elevated IGF-II mRNA and phosphorylation of 4E-BP1 and p70S6k in muscle showing clenbuterol-induced anabolism. Am J Physiol Endocrinol Metab 281 (2001) E676-E682
171. 2-adrenergic receptors and the cardiopulmonary response to exercise. Exerc Sport Sci Rev 36 (2008) 98-105
172. Sockolov R., Irwin B., Dressendorfer R.H., and Bernauer E.M. Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 58 (1977) 195-201
173. Soppa G.K., Smolenski R.T., Latif N., Yuen A.H., Malik A., Karbowska J., et al. Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol 288 (2005) H1468-1476
174. Sorimachi H., Imajoh-Ohmi S., Emori Y., Kawasaki H., Ohno S., Minami Y., et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and m-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 264 (1989) 20106-20111
175. Sporano V., Grasso L., Chem M.E., Chem G.O., Brambilla G., and Loizzo A. Clenbuterol residues in non-liver containing meat as a cause of collective food poisoning. Vet Human Toxicol 40 (1998) 141-143
176. Spurlock D.M., McDaneld T.G., and McIntyre L.M. Changes in skeletal muscle gene expression following clenbuterol administration. BMC Genomics 7 (2006) 320
177. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14 (2004) 395-403
178. Taylor P.B., and Tang Q. Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharm 62 (1984) 384-389
179. 2+ channels. Cardiovasc Res 65 (2005) 28-39
180. Wetzker R., and Bohmer F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4 (2003) 651-657
181. Williams R.S., Caron M.G., and Daniel K. Skeletal muscle β-adrenergic receptors: variations due to fiber type and training. Am J Physiol 246 (1984) E160-E167
182. Windelinckx A., De Mars G., Beunen G., Aerssens J., Delecluse C., Lefevre J., et al. Polymorphisms in the vitamin D receptor gene are associated with muscle strength in men and women. Osteoporos Int 18 (2007) 1235-1242
183. Wong K., Boheler K.R., Bishop J., Petrou M., and Yacoub M.H. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 37 (1998) 115-122
184. Wright L.D., Zhang K.M., McClain L.C., Hsia P.W., Briggs F.N., and Spratt J.A. Salbutamol and the conditioning of latissimus dorsi for cardiomyoplasty. J Surg Res 81 (1999) 209-215
185. i proteins. Circ Res 87 (2000) 635-637
186. 2-adrenergic receptor to Gs and Gi proteins. Sci STKE (2001) RE15
187. i proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84 (1999) 43-52
188. 2-adrenergic signal transduction. Circ Res 85 (1999) 1092-1100
189. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem 269 (1994) 19151-19156
190. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47 (1995) 322-329
191. 1- and β-adrenoceptor signaling in the heart. Trends Pharmacol Sci 27 (2006) 330-337
192. Yamada K., Koshiura R., Mukawa A., Shimo T., Kubo S., and Uesaka I. The comparative toxicity test on cardiotoxic actions among C-78, clorprenaline, isoproterenol, salbutamol and terbutaline. Pharmacomet 13 (1977) 469-496
193. Yimlamai T., Dodd S.L., Borst S.E., and Park S. Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J Appl Physiol 99 (2005) 71-80
194. 2-receptor agonist. Am J Physiol 254 (1988) E726-E732
195. 2-agonist, retards atrophy in denervated muscles. Am J Physiol 252 (1987) E152-E155
196. Zeman R.J., Peng H., Danon M.J., and Etlinger J.D. Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve 23 (2000) 521-528